PFE•businesswire•
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
Summary
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600106.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight manag
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 9, 2025 by businesswire